# A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Source: https://onco.cc/trials/nct03182244/  
OnCo record `nct03182244` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gilteritinib, Cytarabine, Mitoxantrone, Etoposide and Fludarabine in acute myeloid leukaemia, run by Astellas Pharma Inc, active and no longer recruiting.

## Summary

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation is a phase 3 interventional study registered as NCT03182244 by Astellas Pharma Inc, with 276 participants enrolled, started 2017-10-25 and due to reach its primary completion in 2023-12-25. Interventions recorded: Gilteritinib, Cytarabine, Mitoxantrone, Etoposide, G-CSF and Fludarabine. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03182244
- Phase: 3
- Setting: Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
- Sponsor: Astellas Pharma Inc
- Enrolled: 276

## Sources

- ClinicalTrials.gov NCT03182244: https://clinicaltrials.gov/study/NCT03182244

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Cytarabine](https://onco.cc/drugs/cytarabine/), [Etoposide](https://onco.cc/drugs/etoposide/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Gilteritinib](https://onco.cc/drugs/gilteritinib/), [Mitoxantrone](https://onco.cc/drugs/mitoxantrone/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct03182244.json